Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Trevi Therapeutics

Nasdaq:TRVI
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
TRVI
Nasdaq
$48M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The last earnings update was 23 days ago. More info.


Add to Portfolio Compare Print
TRVI Share Price and Events
7 Day Returns
-14.7%
NasdaqGM:TRVI
4.6%
US Pharmaceuticals
2.4%
US Market
1 Year Returns
-
NasdaqGM:TRVI
-2%
US Pharmaceuticals
-10%
US Market
TRVI Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Trevi Therapeutics (TRVI) -14.7% -42.6% -48.2% - - -
US Pharmaceuticals 4.6% -3.1% -7.9% -2% 10% 5.4%
US Market 2.4% -11% -19.4% -10% 9.6% 21.1%
1 Year Return vs Industry and Market
  • No trading data on TRVI.
  • No trading data on TRVI.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Trevi Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Trevi Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is $2.6799.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Trevi Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Trevi Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:TRVI PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-2.28
NasdaqGM:TRVI Share Price ** NasdaqGM (2020-04-07) in USD $2.68
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 24 Publicly-Listed Pharmaceuticals Companies 20.33x
United States of America Market PE Ratio Median Figure of 2,948 Publicly-Listed Companies 12.95x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Trevi Therapeutics.

NasdaqGM:TRVI PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:TRVI Share Price ÷ EPS (both in USD)

= 2.68 ÷ -2.28

-1.18x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Trevi Therapeutics is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Trevi Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Trevi Therapeutics's expected growth come at a high price?
Raw Data
NasdaqGM:TRVI PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.18x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
-8.6%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.91x
United States of America Market PEG Ratio Median Figure of 2,010 Publicly-Listed Companies 0.92x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Trevi Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Trevi Therapeutics's assets?
Raw Data
NasdaqGM:TRVI PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $3.06
NasdaqGM:TRVI Share Price * NasdaqGM (2020-04-07) in USD $2.68
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 181 Publicly-Listed Pharmaceuticals Companies 2.42x
United States of America Market PB Ratio Median Figure of 5,162 Publicly-Listed Companies 1.26x
NasdaqGM:TRVI PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:TRVI Share Price ÷ Book Value per Share (both in USD)

= 2.68 ÷ 3.06

0.88x

* Primary Listing of Trevi Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Trevi Therapeutics is good value based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Trevi Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Trevi Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Trevi Therapeutics expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-8.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Trevi Therapeutics expected to grow at an attractive rate?
  • Unable to compare Trevi Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Trevi Therapeutics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Trevi Therapeutics's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:TRVI Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:TRVI Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts -8.6%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 27.3%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:TRVI Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:TRVI Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 37 -25 3
2023-12-31 5 -40 -46 3
2022-12-31 0 -36 -32 4
2021-12-31 0 -53 -63 4
2020-12-31 0 -35 -36 4
2020-04-08
NasdaqGM:TRVI Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -23 -27
2019-09-30 -22 -28
2019-06-30 -18 -27
2019-03-31 -18 -27
2018-12-31 -18 -26
2018-09-30 -16 -22
2017-12-31 -8 -13

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Trevi Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Trevi Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:TRVI Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Trevi Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:TRVI Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31
2023-12-31 -1.06 -1.06 -1.06 1.00
2022-12-31 -0.80 -0.80 -0.80 1.00
2021-12-31 -1.83 -1.83 -1.83 1.00
2020-12-31 -1.67 -1.67 -1.67 1.00
2020-04-08
NasdaqGM:TRVI Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -2.28
2019-09-30 -3.74
2019-06-30 -9.14
2019-03-31 -60.44
2018-12-31 -58.45
2018-09-30 -49.77
2017-12-31 -29.81

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Trevi Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Trevi Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Trevi Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Trevi Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Trevi Therapeutics's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Trevi Therapeutics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Trevi Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Trevi Therapeutics's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Trevi Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Trevi Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:TRVI Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -26.75 7.31 19.34
2019-09-30 -27.57 6.77 19.04
2019-06-30 -27.32 5.98 17.14
2019-03-31 -26.59 5.03 15.05
2018-12-31 -25.58 4.34 14.07
2018-09-30 -21.71 3.55 11.15
2017-12-31 -12.54 2.14 6.10
2016-12-31 -6.71 1.71 6.91

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Trevi Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Trevi Therapeutics has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Trevi Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Trevi Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Trevi Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Trevi Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Trevi Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Trevi Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Trevi Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Trevi Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Trevi Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Trevi Therapeutics Company Filings, last reported 3 months ago.

NasdaqGM:TRVI Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 54.55 0.00 57.31
2019-09-30 60.71 0.00 63.52
2019-06-30 67.70 0.00 71.39
2019-03-31 12.68 0.00 12.95
2018-12-31 6.25 1.10 7.20
2018-09-30 12.04 0.96 13.53
2017-12-31 14.78 5.29 22.02
2016-12-31 -17.41 22.11 8.29
  • Trevi Therapeutics has no debt.
  • Trevi Therapeutics currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Trevi Therapeutics has sufficient cash runway for 2.5 years based on current free cash flow.
  • Trevi Therapeutics has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 27% each year.
X
Financial health checks
We assess Trevi Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Trevi Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Trevi Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Trevi Therapeutics dividends.
If you bought $2,000 of Trevi Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Trevi Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Trevi Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:TRVI Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 2.9%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1935 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:TRVI Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Trevi Therapeutics has not reported any payouts.
  • Unable to verify if Trevi Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Trevi Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Trevi Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Trevi Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Trevi Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Trevi Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Trevi Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jennifer Good
COMPENSATION $528,250
AGE 54
TENURE AS CEO 9.1 years
CEO Bio

Ms. Jennifer L. Good co-founded Trevi Therapeutics, Inc., in March 2011 and has been its Chief Executive Officer and President since March 2011. Ms. Good serves as Director at Rhythm Pharmaceuticals, Inc. since June 19, 2019. Ms. Good served as Chief Executive Officer and President of Penwest Pharmaceuticals Co. since June 2006 and November 23, 2005 respectively. Ms. Good served as the Chief Operating Officer of Penwest Pharmaceuticals from November 23, 2005 to June 2006; Chief Financial Officer from February 1997 to June 2006; Senior Vice President of Finance since 1997 and served as its Principal Accounting Officer and Company Secretary. She also served as Corporate Controller for Penford Corp. from 1993 to 1997. She led Penwest Pharmaceuticals Co.’s finance, human resources, corporate communications and information technology functions. Prior to joining Penwest, Ms. Good served as Corporate Controller and Corporate Director of Finance of Penford Corporation, Penwest’s former parent company, from 1993 to 1997. From 1987 to 1993, she served in a number of client management positions at Ernst & Young LLP, ultimately as audit Manager. She worked primarily with clients in the high technology, biotechnology and healthcare industries. She served as an Executive Director of Penwest Pharmaceuticals Co. since June 2006. She serves as a Director at Trevi Therapeutics, Inc. She served as Director of Juniper Pharmaceuticals, Inc. since September 11, 2017 until August 14, 2018. She served as a Director of XTL Biopharmaceuticals Ltd. since October 2008. In 2007, she received the Connecticut Technology Counsel’s Small Business Innovation and Leadership Award. She is a Certified Public Accountant in the state of Washington. Ms. Good received a Bachelor of Business Administration degree with a Concentration in Accounting from Pacific Lutheran University in 1987

CEO Compensation
  • Jennifer's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Jennifer's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Trevi Therapeutics management team in years:

2.3
Average Tenure
62
Average Age
  • The tenure for the Trevi Therapeutics management team is about average.
Management Team

Jennifer Good

TITLE
Co-Founder
COMPENSATION
$528K
AGE
54
TENURE
9.1 yrs

Chris Seiter

TITLE
Chief Financial Officer
COMPENSATION
$890K
AGE
51
TENURE
1.9 yrs

Yann Mazabraud

TITLE
Chief Commercial Officer & Head of International
COMPENSATION
$1M
AGE
46
TENURE
1.8 yrs

Thomas Sciascia

TITLE
Co-Founder & Chief Medical Officer
AGE
66
TENURE
9.1 yrs

Helena Brett-Smith

TITLE
Chief Development Officer
AGE
62
TENURE
2.6 yrs

Amale Hawi

TITLE
Senior Vice President of CMC
AGE
65
TENURE
1.3 yrs

Frank Muscolo

TITLE
Controller
AGE
62
Board of Directors Tenure

Average tenure and age of the Trevi Therapeutics board of directors in years:

2.8
Average Tenure
59
Average Age
  • The average tenure for the Trevi Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

David Meeker

TITLE
Chairman
COMPENSATION
$25K
AGE
65
TENURE
2.8 yrs

Jennifer Good

TITLE
Co-Founder
COMPENSATION
$528K
AGE
54

Mike Heffernan

TITLE
Independent Director
COMPENSATION
$25K
AGE
55
TENURE
3.2 yrs

Anne VanLent

TITLE
Independent Director
COMPENSATION
$112K
AGE
71
TENURE
1.5 yrs

Jeff Bernhard

TITLE
Member of Clinical Advisory Board
TENURE
7.1 yrs

Dawn McGuire

TITLE
Member of Clinical Advisory Board
TENURE
7.1 yrs

Ed Mathers

TITLE
Independent Director
AGE
59
TENURE
2.8 yrs

Annie Mitsak

TITLE
Independent Director
AGE
34
TENURE
1.7 yrs

Jim Cassella

TITLE
Director
AGE
64
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
13. May 19 Buy Aperture Venture Partners, LLC Company 09. May 19 09. May 19 112,000 $10.00 $1,120,000
13. May 19 Buy TPG Capital, L.P. Company 09. May 19 09. May 19 800,000 $10.00 $8,000,000
13. May 19 Buy Jennifer Good Individual 09. May 19 09. May 19 11,250 $10.00 $112,500
13. May 19 Buy David Meeker Individual 09. May 19 09. May 19 11,250 $10.00 $112,500
13. May 19 Buy New Enterprise Associates, Inc. Company 09. May 19 09. May 19 2,500,000 $10.00 $25,000,000
13. May 19 Buy Omega Fund Management, LLC Company 09. May 19 09. May 19 481,000 $10.00 $4,810,000
13. May 19 Buy Mellon Family Investment Co Company 09. May 19 09. May 19 100,000 $10.00 $1,000,000
13. May 19 Buy Michael Heffernan Individual 09. May 19 09. May 19 2,500 $10.00 $25,000
13. May 19 Buy Richard King Mellon Foundation, Endowment Arm Company 09. May 19 09. May 19 100,000 $10.00 $1,000,000
13. May 19 Buy Anne VanLent Individual 09. May 19 09. May 19 5,000 $10.00 $50,000
13. May 19 Buy Lundbeckfond Invest A/S Company 09. May 19 09. May 19 375,000 $10.00 $3,750,000
X
Management checks
We assess Trevi Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Trevi Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Should You Take Comfort From Insider Transactions At Trevi Therapeutics, Inc. (NASDAQ:TRVI)?

View our latest analysis for Trevi Therapeutics Trevi Therapeutics Insider Transactions Over The Last Year Over the last year, we can see that the biggest insider purchase was by Co-Founder Jennifer Good for US$113k worth of shares, at about US$10.00 per share. … In the last twelve months Trevi Therapeutics insiders were buying shares, but not selling. … From our data, it seems that Trevi Therapeutics insiders own 5.8% of the company, worth about US$5.2m.

Simply Wall St -

Company Info

Description

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company’s nalbuphine ER, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. Trevi Therapeutics, Inc. was founded in 2011 and is headquartered in New Haven, Connecticut.

Details
Name: Trevi Therapeutics, Inc.
TRVI
Exchange: NasdaqGM
Founded: 2011
$47,794,864
17,834,570
Website: http://www.trevitherapeutics.com
Address: Trevi Therapeutics, Inc.
195 Church Street,
14th Floor,
New Haven,
Connecticut, 06510,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM TRVI Common Shares Nasdaq Global Market US USD 07. May 2019
Number of employees
Current staff
Staff numbers
17
Trevi Therapeutics employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 04:54
End of day share price update: 2020/04/07 00:00
Last estimates confirmation: 2020/04/06
Last earnings filing: 2020/03/16
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.